These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 23836346)

  • 21. Aflibercept--a decoy VEGF receptor.
    Ciombor KK; Berlin J
    Curr Oncol Rep; 2014 Feb; 16(2):368. PubMed ID: 24445500
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aflibercept and its role in the treatment of colorectal cancer--letter.
    Sinicrope FA; Williamson EE; Borgeson DD
    Clin Cancer Res; 2013 Nov; 19(21):6057. PubMed ID: 24043464
    [No Abstract]   [Full Text] [Related]  

  • 23. Aflibercept: a novel VEGF targeted agent to explore the future perspectives of anti-angiogenic therapy for the treatment of multiple tumors.
    Sharma T; Dhingra R; Singh S; Sharma S; Tomar P; Malhotra M; Bhardwaj TR
    Mini Rev Med Chem; 2013 Apr; 13(4):530-40. PubMed ID: 23317499
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Building a better Trap.
    Hood JD; Cheresh DA
    Proc Natl Acad Sci U S A; 2003 Jul; 100(15):8624-5. PubMed ID: 12861079
    [No Abstract]   [Full Text] [Related]  

  • 25. The value and effectiveness of angiogenesis inhibitors for colorectal cancer.
    Venook AP
    Clin Adv Hematol Oncol; 2015 Sep; 13(9):561-3. PubMed ID: 26452184
    [No Abstract]   [Full Text] [Related]  

  • 26. [New molecular targeting drugs for metastatic colorectal cancer].
    Komatsu Y; Harada K; Fukushima H; Yuki S
    Nihon Rinsho; 2014 Jan; 72(1):120-6. PubMed ID: 24597359
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ulcerations on abdominal wound scar associated with aflibercept therapy.
    Rivas-Tolosa N; Calomarde L; Bancalari B; Guillén C; Sanmartín O
    J Dermatol; 2016 Sep; 43(9):1095-6. PubMed ID: 26970060
    [No Abstract]   [Full Text] [Related]  

  • 28. Evaluation of aflibercept in the treatment of metastatic colorectal cancer.
    Macarulla T; Sauri T; Tabernero J
    Expert Opin Biol Ther; 2014 Oct; 14(10):1493-505. PubMed ID: 25152076
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Chemotherapy with molecular targeting agents for colorectal cancer].
    Bando H; Ohtsu A
    Nihon Rinsho; 2012 Nov; 70 Suppl 8():468-74. PubMed ID: 23513885
    [No Abstract]   [Full Text] [Related]  

  • 30. Sequencing therapies: the role of targeted agents in metastatic colorectal cancer.
    Oestreicher P
    ONS Connect; 2007; 22(8 Suppl):37-8. PubMed ID: 17824557
    [No Abstract]   [Full Text] [Related]  

  • 31. [Sequential inhibition of angiogenesis in metastatic colorectal cancer: activity and efficacy of aflibercept].
    Martines C; Cordio S; Bordonaro R
    Recenti Prog Med; 2015 May; 106(5):239e-43e. PubMed ID: 25994542
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Regorafenib (Stivarga) for metastatic colorectal cancer and GIST.
    Med Lett Drugs Ther; 2013 Apr; 55(1415):e36. PubMed ID: 23836345
    [No Abstract]   [Full Text] [Related]  

  • 33. Aflibercept (VEGF Trap-Eye) for the treatment of exudative age-related macular degeneration.
    Stewart MW
    Expert Rev Clin Pharmacol; 2013 Mar; 6(2):103-13. PubMed ID: 23473589
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Switching anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration.
    Schachat AP
    Am J Ophthalmol; 2013 Jul; 156(1):1-2.e1. PubMed ID: 23791369
    [No Abstract]   [Full Text] [Related]  

  • 35. Comprehensive biophysical and functional study of ziv-aflibercept: characterization and forced degradation.
    Hermosilla J; Pérez-Robles R; Salmerón-García A; Casares S; Cabeza J; Bones J; Navas N
    Sci Rep; 2020 Feb; 10(1):2675. PubMed ID: 32060315
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular mechanisms and targeting of colorectal cancer.
    Vanhoefer U
    Semin Oncol; 2005 Dec; 32(6 Suppl 8):7-10. PubMed ID: 16360005
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Some problems facing the molecular targeting therapy for colorectal cancer].
    Xu JM
    Zhonghua Zhong Liu Za Zhi; 2009 May; 31(5):321-3. PubMed ID: 19799077
    [No Abstract]   [Full Text] [Related]  

  • 38. Aflibercept (eylea) for age-related macular degeneration.
    Med Lett Drugs Ther; 2012 Feb; 54(1383):9-10. PubMed ID: 22354219
    [No Abstract]   [Full Text] [Related]  

  • 39. [Anti-VEGF therapy of neovascular age-related macular degeneration: therapeutic strategies status December 2012].
    Pauleikhoff D; Bertram B; Holz FG; Kirchhof B; Bartz-Schmidt U; Bornfeld N; Bresgen M; Eter N; Friedrichs W; Heimann H; Helbig H; Hörauf H; Kampik A; Lemmen KD; Roider J; Ziemssen F
    Klin Monbl Augenheilkd; 2013 Feb; 230(2):170-7. PubMed ID: 23430681
    [No Abstract]   [Full Text] [Related]  

  • 40. Intraperitoneal ziv-aflibercept effectively manages refractory ascites in colorectal cancer patients.
    Lu CS; Lin JK; Chen WS; Lin TC; Jiang JK; Yang SH; Wang HS; Chang SC; Lan YT; Lin CC; Lin HH; Teng HW
    Oncotarget; 2017 May; 8(22):36707-36715. PubMed ID: 27888621
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.